Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | CRHR1 | P34998 | 11/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5865730 | 0.80 | CRHR1 (0.39) | CRHR1 | |
| SCHEMBL6572937 | 0.77 | CRHR1 (0.54) | CRHR1CYP3A4DPP4 | |
| SCHEMBL5865767 | 0.76 | CRHR1 (0.38) | GAACRHR1ALDH1A1 | |
| SCHEMBL6571986 | 0.76 | MEN1 (0.41) | KMT2ACRHR1CYP3A4SMN1; SMN2DPP4 | |
| SCHEMBL9424150 | 0.75 | KMT2A (0.38) | KMT2ACRHR1CYP3A4TSHRALDH1A1 | |
| SCHEMBL6572154 | 0.75 | MEN1 (0.47) | KMT2AGAACRHR1ALDH1A1MEN1 | |
| SCHEMBL12656213 | 0.74 | CRHR1 (0.47) | KMT2ACRHR1ALDH1A1MEN1 | |
| SCHEMBL6571546 | 0.73 | CRHR1 (0.42) | KMT2ACRHR1ALDH1A1TP53MEN1 | |
| SCHEMBL6573371 | 0.73 | CRHR1 (0.41) | KMT2ACRHR1CYP3A4TP53DPP4 | |
| SCHEMBL6572395 | 0.71 | CRHR1 (0.48) | CRHR1CYP3A4TSHRDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7056925-B2 | for example, N-{2-[benzyl(2-hydroxyethyl)amino]-5-bromophenyl)}-N'-(5-cyano-2-pyrazinyl)urea, N-{5-bromo-2-[(2-hydroxy-2-phenylethyl)(methyl)amino]phenyl}-N'-(5-cyano-2-pyrazinyl)urea; anticarcinogenic agents | ABBOTT LABORATORIES (US) | 2006-06-06 | — | — | US | disclosed |
| EP-1534692-A1 | UREA DERIVATIVES AS KINASE INHIBITORS | Abbott Laboratories (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20040259885-A1 | Urea kinase inhibitors | ABBVIE INC. | 2004-12-23 | — | — | US | disclosed |
| WO-2004014876-A1 | UREA DERIVATIVES AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2004-02-19 | — | — | WO | disclosed |
| US-20040034038-A1 | Urea kinase inhibitors | ABBOTT LABORATORIES | 2004-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034038-A1 | Urea kinase inhibitors | UCK2, CMPK1, CDK2 | KMT2A 2855/4885GAA 1078/4885CRHR1 4751/4885 |
| US-20040259885-A1 | Urea kinase inhibitors | UCK2, CMPK1, CDK2 | KMT2A 2855/4885GAA 1078/4885CRHR1 4751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.